All patients
Age < 65y (younger) Age > 75y (older) ECOG 0 ECOG 1 Gender, female Gender, male PD-L1 < 1% PD-L1 > 1% stage III (locally advanced) stage IV (metastatic)
Top evidence (RCT only, high risk of bias excluded)
Best available evidence (possibly low or very low)
All RCTs
All studies (RCT+OBS)
studies
mesothelioma (MS), Immune checkpoint association vs. platinum-based chemotherapy, meta-analysis of study results Outcome TE 95% CI n k I2 ROB Pub. bias deaths (OS)detailed results CheckMate 743, 2021 0.74 [0.60; 0.91]
0.74 [0.60 ; 0.91 ] CheckMate 743, 2021 1 0% NA not evaluable progression or deaths (PFS)detailed results CheckMate 743, 2021 1.00 [0.82; 1.21]
1.00 [0.82 ; 1.21 ] CheckMate 743, 2021 1 0% 605 NA not evaluable DCRdetailed results CheckMate 743, 2021 0.57 [0.38; 0.87]
0.57 [0.38 ; 0.87 ] CheckMate 743, 2021 1 0% 605 NA not evaluable objective responses (ORR)detailed results CheckMate 743, 2021 0.88 [0.64; 1.22]
0.88 [0.64 ; 1.22 ] CheckMate 743, 2021 1 0% 605 NA not evaluable STRAE (any grade)detailed results CheckMate 743, 2021 0.92 [0.65; 1.31]
0.92 [0.65 ; 1.31 ] CheckMate 743, 2021 1 0% 584 NA not evaluable TRAE leading to death (grade 5)detailed results CheckMate 743, 2021 2.86 [0.30; 27.64]
2.86 [0.30 ; 27.64 ] CheckMate 743, 2021 1 0% 584 NA not evaluable TRAE leading to discontinuation (any grade)detailed results CheckMate 743, 2021 1.59 [1.05; 2.41]
1.59 [1.05 ; 2.41 ] CheckMate 743, 2021 1 0% 584 NA not evaluable TRAE leading to discontinuation (grade 3-4)detailed results CheckMate 743, 2021 2.21 [1.28; 3.81]
2.21 [1.28 ; 3.81 ] CheckMate 743, 2021 1 0% 584 NA not evaluable Abdominal pain TRAE (grade 3-4)detailed results CheckMate 743, 2021 0.47 [0.02; 14.14]
0.47 [0.02 ; 14.14 ] CheckMate 743, 2021 1 0% 584 NA not evaluable Acute kidney injury TRAE (grade 3-4)detailed results CheckMate 743, 2021 7.66 [0.40; 145.59]
7.66 [0.40 ; 145.59 ] CheckMate 743, 2021 1 0% 584 NA not evaluable Adrenal insufficiency TRAE (grade 3-4)detailed results CheckMate 743, 2021 1.90 [0.06; 56.75]
1.90 [0.06 ; 56.75 ] CheckMate 743, 2021 1 0% 584 NA not evaluable Anaemia TRAE (grade 3-4)detailed results CheckMate 743, 2021 0.03 [0.00; 0.19]
0.03 [0.00 ; 0.19 ] CheckMate 743, 2021 1 0% 584 NA not evaluable Arthralgia TRAE (grade 3-4)detailed results CheckMate 743, 2021 1.90 [0.06; 56.75]
1.90 [0.06 ; 56.75 ] CheckMate 743, 2021 1 0% 584 NA not evaluable Arthritis TRAE (grade 3-4)detailed results CheckMate 743, 2021 3.81 [0.17; 84.75]
3.81 [0.17 ; 84.75 ] CheckMate 743, 2021 1 0% 584 NA not evaluable Asthenia TRAE (grade 3-4)detailed results CheckMate 743, 2021 0.04 [0.00; 0.64]
0.04 [0.00 ; 0.64 ] CheckMate 743, 2021 1 0% 584 NA not evaluable Colitis TRAE (grade 3-4)detailed results CheckMate 743, 2021 6.76 [0.83; 55.31]
6.76 [0.83 ; 55.31 ] CheckMate 743, 2021 1 0% 584 NA not evaluable Constipation TRAE (grade 3-4)detailed results CheckMate 743, 2021 0.47 [0.02; 14.14]
0.47 [0.02 ; 14.14 ] CheckMate 743, 2021 1 0% 584 NA not evaluable Decreased appetite TRAE (grade 3-4)detailed results CheckMate 743, 2021 0.95 [0.13; 6.76]
0.95 [0.13 ; 6.76 ] CheckMate 743, 2021 1 0% 584 NA not evaluable Dermatitis acneiform TRAE (grade 3-4)detailed results CheckMate 743, 2021 1.90 [0.06; 56.75]
1.90 [0.06 ; 56.75 ] CheckMate 743, 2021 1 0% 584 NA not evaluable Diarrhoea TRAE (grade 3-4)detailed results CheckMate 743, 2021 4.86 [1.06; 22.39]
4.86 [1.06 ; 22.39 ] CheckMate 743, 2021 1 0% 584 NA not evaluable Dyspnoea TRAE (grade 3-4)detailed results CheckMate 743, 2021 0.47 [0.02; 14.14]
0.47 [0.02 ; 14.14 ] CheckMate 743, 2021 1 0% 584 NA not evaluable Fatigue TRAE (grade 3-4)detailed results CheckMate 743, 2021 0.56 [0.13; 2.38]
0.56 [0.13 ; 2.38 ] CheckMate 743, 2021 1 0% 584 NA not evaluable Febrile neutropenia TRAE (grade 3-4)detailed results CheckMate 743, 2021 0.16 [0.01; 3.14]
0.16 [0.01 ; 3.14 ] CheckMate 743, 2021 1 0% 584 NA not evaluable Hepatitis TRAE (grade 3-4)detailed results CheckMate 743, 2021 3.81 [0.17; 84.75]
3.81 [0.17 ; 84.75 ] CheckMate 743, 2021 1 0% 584 NA not evaluable Hypersensitivity TRAE (grade 3-4)detailed results CheckMate 743, 2021 1.90 [0.06; 56.75]
1.90 [0.06 ; 56.75 ] CheckMate 743, 2021 1 0% 584 NA not evaluable Hypothyroidism TRAE (grade 3-4)detailed results CheckMate 743, 2021 0.95 [0.02; 47.87]
0.95 [0.02 ; 47.87 ] CheckMate 743, 2021 1 0% 584 NA not evaluable Increase AST TRAE (grade 3-4)detailed results CheckMate 743, 2021 5.73 [0.29; 114.85]
5.73 [0.29 ; 114.85 ] CheckMate 743, 2021 1 0% 584 NA not evaluable Increased ALT TRAE (grade 3-4)detailed results CheckMate 743, 2021 9.61 [0.52; 176.72]
9.61 [0.52 ; 176.72 ] CheckMate 743, 2021 1 0% 584 NA not evaluable Increased lipase level TRAE (grade 3-4)detailed results CheckMate 743, 2021 11.79 [1.52; 91.29]
11.79 [1.52 ; 91.29 ] CheckMate 743, 2021 1 0% 584 NA not evaluable Infusion-related reactions TRAE (grade 3-4)detailed results CheckMate 743, 2021 5.73 [0.29; 114.85]
5.73 [0.29 ; 114.85 ] CheckMate 743, 2021 1 0% 584 NA not evaluable Maculopapular rash TRAE (grade 3-4)detailed results CheckMate 743, 2021 1.90 [0.06; 56.75]
1.90 [0.06 ; 56.75 ] CheckMate 743, 2021 1 0% 584 NA not evaluable Mucosal inflammation TRAE (grade 3-4)detailed results CheckMate 743, 2021 0.24 [0.01; 5.24]
0.24 [0.01 ; 5.24 ] CheckMate 743, 2021 1 0% 584 NA not evaluable Myocarditis TRAE (grade 3-4)detailed results CheckMate 743, 2021 1.90 [0.06; 56.75]
1.90 [0.06 ; 56.75 ] CheckMate 743, 2021 1 0% 584 NA not evaluable Myositis TRAE (grade 3-4)detailed results CheckMate 743, 2021 3.81 [0.17; 84.75]
3.81 [0.17 ; 84.75 ] CheckMate 743, 2021 1 0% 584 NA not evaluable Nausea TRAE (grade 3-4)detailed results CheckMate 743, 2021 0.13 [0.02; 1.08]
0.13 [0.02 ; 1.08 ] CheckMate 743, 2021 1 0% 584 NA not evaluable Neutropenia TRAE (grade 3-4)detailed results CheckMate 743, 2021 0.04 [0.01; 0.16]
0.04 [0.01 ; 0.16 ] CheckMate 743, 2021 1 0% 584 NA not evaluable Pancytopenia TRAE (grade 3-4)detailed results CheckMate 743, 2021 0.09 [0.01; 1.71]
0.09 [0.01 ; 1.71 ] CheckMate 743, 2021 1 0% 584 NA not evaluable Pneumonia TRAE (grade 3-4)detailed results CheckMate 743, 2021 0.47 [0.02; 14.14]
0.47 [0.02 ; 14.14 ] CheckMate 743, 2021 1 0% 584 NA not evaluable Pneumonitis TRAE (grade 3-4)detailed results CheckMate 743, 2021 1.90 [0.06; 56.75]
1.90 [0.06 ; 56.75 ] CheckMate 743, 2021 1 0% 584 NA not evaluable Pruritus TRAE (grade 3-4)detailed results CheckMate 743, 2021 5.73 [0.29; 114.85]
5.73 [0.29 ; 114.85 ] CheckMate 743, 2021 1 0% 584 NA not evaluable Pyrexia TRAE (grade 3-4)detailed results CheckMate 743, 2021 0.47 [0.02; 14.14]
0.47 [0.02 ; 14.14 ] CheckMate 743, 2021 1 0% 584 NA not evaluable Rash TRAE (grade 3-4)detailed results CheckMate 743, 2021 5.73 [0.29; 114.85]
5.73 [0.29 ; 114.85 ] CheckMate 743, 2021 1 0% 584 NA not evaluable Sepsis TRAE (grade 3-4)detailed results CheckMate 743, 2021 0.47 [0.02; 14.14]
0.47 [0.02 ; 14.14 ] CheckMate 743, 2021 1 0% 584 NA not evaluable Stomatitis TRAE (grade 3-4)detailed results CheckMate 743, 2021 0.47 [0.02; 14.14]
0.47 [0.02 ; 14.14 ] CheckMate 743, 2021 1 0% 584 NA not evaluable Thrombocytopenia TRAE (grade 3-4)detailed results CheckMate 743, 2021 0.18 [0.04; 0.85]
0.18 [0.04 ; 0.85 ] CheckMate 743, 2021 1 0% 584 NA not evaluable Vomiting TRAE (grade 3-4)detailed results CheckMate 743, 2021 0.08 [0.00; 1.39]
0.08 [0.00 ; 1.39 ] CheckMate 743, 2021 1 0% 584 NA not evaluable 0.0 20.0 1.0 relative treatment effect www.metaEvidence.org 2024-10-05 13:34 +02:00
TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers);
k: number of studies; n: total number of patients;
ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
studied treatment is better when TE > 1;
studied treatment is better when TE < 1;
pathologies: 139,222,223,221
- treatments: 856,634,861,416,864,769,980